Radiographic Progression of Structural Joint Damage in Patients With Active Psoriatic Arthritis Treated With Ixekizumab Over 52 Weeks

Désirée van der Heijde,1 Masato Okada,2 Chin Leo,3 Catherine L. Shuler,3 Suchititha Rathmann,3 Chen-Yen Lin4 Philip J. Mease4
1Leiden University Medical Centre, Leiden, The Netherlands; 2St. Luke’s International Hospital, Tokyo, Japan; 3Eli Lilly and Company, Indianapolis, USA; 4Swedish Medical Center and University of Washington, Seattle, USA

BACKGROUND
Ixekizumab is a high-affinity monononal antibody that selectively targets interleukin-17A.

Efficacy of ixekizumab in providing persistence of clinical responses through 52 weeks of treatment has been shown in SPIRIT-P1.1

OBJECTIVE
To assess the impact of ixekizumab on the progression of structural joint damage in patients with psoriatic arthritis who were treated for up to 52 weeks in SPIRIT-P1.

METHODS
Study Design
SPIRIT-P1

METHODS
Study Design
SPIRIT-P1

RESULTS
Assessment of Structural Joint Damage
• Assessed using the van der Heijde modified Total Sharp Score (mTSS)
  - Quantifies the extent of bone erosions (20 locations per hand/wrist, 12 locations per foot) and joint space narrowing (20 locations per hand/wrist, 6 locations per foot)
  - Total mTSS score is the sum of bone erosion and joint space narrowing scores
  • Scores range from 0 to 528
  • Higher scores represent greater damage
• Analysis of mTSS scores as percentage change from baseline to Week 52

Statistical Analysis
• Extension period population
  - All patients who entered the extension period and received ≥1 dose of study medication during this period
• Prespecified analysis
  - mTSS data were excluded if the radiograph was taken after the scheduled visit date
  - Presented as mean change from baseline to Week 52
• Post hoc analysis
  - mTSS data from radiographs taken after the scheduled visit date were interpolated
  - Presented as mean change from baseline to Week 52
• Cumulative probability plots were created to visualize patient-level data
• Summaries are presented for the proportion of patients with no radiographic progression, defined as the mTSS change from baseline to Week 52 ≥0.05, and 1.32 (the smallest detectable change from baseline to Week 52 in this study)
• Missing data were imputed using linear extrapolation method if ≥1 postbaseline value was available

DISCUSSIONS
• Over a 52-week period, minimal changes in mTSS were observed in patients with psoriatic arthritis who entered the Extension Period and were treated with ixekizumab 80 mg every 2 or 4 weeks

Acknowledgments
• The authors would like to thank:
  - All patients and investigators in the study
  - Eli Lilly and Company for providing research support

References
• [List of references]

Sponsored by Eli Lilly and Company and one of its subsidiaries